Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
Press release – No. 6 / 2023 Zealand Pharma Presents Results from Phase 1 Clinical Trial of Amylin Analog ZP8396 at ADA Scientific Sessions Body weight reductions reached up to a mean...
-
Press Release No. 5 / 2023 Data shows nearly 19% weight loss in people with overweight or obesity in Boehringer Ingelheim and Zealand Pharma Phase II trial with...
-
Company announcement – No. 25 / 2023 Zealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee Warrants Copenhagen, Denmark, June 8, 2023 – Zealand Pharma A/S (“Zealand”)...
-
Press release – No. 4 / 2023 Zealand Pharma to Participate in Upcoming Healthcare Conferences Copenhagen, Denmark, June 6, 2023 – Zealand Pharma A/S (Nasdaq Copenhagen: ZEAL) (CVR-no. 20045078),...
-
Company announcement – No. 24 / 2023 Total number of shares and voting rights in Zealand Pharma at May 31, 2023 Copenhagen, Denmark, May 31, 2023 – Zealand Pharma A/S (“Zealand”)...
-
Company announcement – No. 23 / 2023 Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons ...
-
Company announcement – No. 22 / 2023 Zealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee Warrants Copenhagen, Denmark, May 23, 2023 – Zealand Pharma A/S...
-
Company announcement – No. 21 / 2023 Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons ...
-
Company announcement - No. 20 / 2023 Zealand Pharma Announces Financial Results for the First Quarter of 2023 Positive topline data from obesity portfolioOn track for two regulatory submissions...
-
Boehringer Ingelheim and Zealand Pharma announce phase II trial showed 14.9% weight loss in people living with obesity or overweight Phase II dose-finding trial met primary endpoint after 46...